Cargando…
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
The α(2)-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455846/ https://www.ncbi.nlm.nih.gov/pubmed/26064054 http://dx.doi.org/10.2147/NDT.S65735 |